Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Carcinoma, Renal Cell 23Sarcoma 18Neoplasms 8Neoplasm Metastasis 8Breast Neoplasms 8Ovarian Neoplasms 7Carcinoma, Non-Small-Cell Lung 7Fallopian Tube Neoplasms 6Liposarcoma 5Leiomyosarcoma 5Hemangiosarcoma 5Sarcoma, Synovial 4Neurofibrosarcoma 4Lung Neoplasms 4Kidney Neoplasms 4Histiocytoma, Malignant Fibrous 4Urinary Bladder Neoplasms 3Recurrence 3Prostatic Neoplasms 3Glioblastoma 3Thyroid Carcinoma, Anaplastic 2Small Cell Lung Carcinoma 2Sarcoma, Alveolar Soft Part 2Pancreatic Neoplasms 2Neuroendocrine Tumors 2Melanoma 2Gliosarcoma 2Fibrosarcoma 2Dermatofibrosarcoma 2Clear-cell metastatic renal cell carcinoma 2

Interventions

Sunitinib 3pembrolizumab 2pazopanib 2Axitinib 2aldesleukin 1Radiosurgery 1Nivolumab 1Nephrectomy 1Metastasectomy 1LY2510924 1Ipilimumab 1Interleukin-2 1Immunoglobulin G 1Cytoreduction Surgical Procedures 1Ascorbic Acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Clear-cell metastatic renal cell carcinoma × pazopanib × Clear all
NCT03334409 2022-03-31

Pazopanib Hydrochloride With or Without Ascorbic Acid in Treating Patients With Kidney Cancer That Is Metastatic or Cannot Be Removed by Surgery

Academic and Community Cancer Research United

Phase 2 Terminated
5 enrolled 16 charts
Genitourinary

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

NCT01472081 2021-12-02

Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate 016)

Bristol-Myers Squibb

Phase 1 Completed
194 enrolled 18 charts
Genitourinary

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡